RECORD // Company

Unicycive Therapeutics, Inc.

Formerly: Unicycive Therapeutics, Inc.

Built 2026-11-22T03:00:20Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (6)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

2 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-16 · accession 0001213900-26-120081

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-6,997,0003 months ended 2026-09-3010-Q2026-11-160001213900-26-1200812026-11-22 03:00 UTCReport an error
Cash and cash equivalents$41,966,000at 2026-09-3010-Q2026-11-160001213900-26-1200812026-11-22 03:00 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue, Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001766140
Ticker
UNCY
EIN
813638692
CUSIP
90466Y202
Record ID
sx:sec:0001766140

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

31 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-22 03:00 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-16SEC EDGAR company profile2026-11-22 03:00 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profile2026-11-22 03:00 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-22 03:00 UTCReport an error
Business address1975 W. EL CAMINO REAL, SUITE 204, MOUNTAIN VIEW, CA, 940402026-11-16SEC EDGAR company profile2026-11-22 03:00 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-22 03:00 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-26,555,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 03:00 UTCReport an error
Total assets (at 2025-12-31)$49,135,0002025-12-3110-K, XBRL Assets2026-11-22 03:00 UTCReport an error
Stockholders' equity (at 2025-12-31)$30,197,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 03:00 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$29,198,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 03:00 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-31,317,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 03:00 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$24,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 03:00 UTCReport an error
Operating lease liabilities (at 2025-12-31)$117,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 03:00 UTCReport an error
Form D total offering amount (D filed 2024-03-20)$50,000,0002024-03-20D2026-11-22 03:00 UTCReport an error
Form D total amount sold (D filed 2024-03-20)$50,000,0002024-03-20D2026-11-22 03:00 UTCReport an error
Form D industry groupBiotechnology2024-03-20D2026-11-22 03:00 UTCReport an error
Form D revenue rangeDecline to Disclose2024-03-20D2026-11-22 03:00 UTCReport an error
Form D date of first sale2024-03-132024-03-20D2026-11-22 03:00 UTCReport an error
8-K Item 5.02, Departure (filed 2026-09-29)of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. On September 28, 2026, Unicycive Therapeutics, Inc. (the “Company”) appointed Meredith S. Manning as an independent director on the Company’s board of directors, effective October 1, 2026. Ms. Manning will serve on each of the Audit, Compensation and Nominating and Corporate Governance Committees, and also as the Chairperson of the Nominating and Corporate Governance Committee. Meredith S. Manning, M.B.A., has more than 25 years of global biopharmaceutical experience. Most recently, she served as Chief Commercial Officer of Soleno Therapeutics, Inc. from 2024 until its acquisition by Neurocrine…2026-09-29SEC EDGAR 8-K 0001213900-26-104314 (text as filed, excerpt)2026-11-22 03:00 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-09-29)On September 29, 2026, the Company issued a press release announcing resubmission of a New Drug Application for Oxylanthanum Carbonate. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein (except for the fourth paragraph therein).2026-09-29SEC EDGAR 8-K 0001213900-26-104314 (text as filed, excerpt)2026-11-22 03:00 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Conditions (filed 2026-08-12)On August 12, 2026, Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2026 and provided a business update. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing. Item 9.01. Financial Statements and Exhibits…2026-08-12SEC EDGAR 8-K 0001213900-26-088061 (text as filed, excerpt)2026-11-22 03:00 UTCReport an error
Largest institutional holder #1 (13F as filed): Nantahala Capital Management, LLC$13,145,5722026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:00 UTCReport an error
Largest institutional holder #2 (13F as filed): BlackRock, Inc.$6,628,7572026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:00 UTCReport an error
Largest institutional holder #3 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$5,025,2462026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:00 UTCReport an error
Largest institutional holder #4 (13F as filed): Octagon Capital Advisors LP$4,690,0002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:00 UTCReport an error
Largest institutional holder #5 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$2,646,0432026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:00 UTCReport an error
Largest institutional holder #6 (13F as filed): Vivo Capital, LLC$2,579,5002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:00 UTCReport an error
Largest institutional holder #7 (13F as filed): MARSHALL WACE, LLP$2,569,4732026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:00 UTCReport an error
Largest institutional holder #8 (13F as filed): Logos Global Management LP$2,221,0102026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:00 UTCReport an error
Largest institutional holder #9 (13F as filed): STATE STREET CORP$2,111,2602026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:00 UTCReport an error
Largest institutional holder #10 (13F as filed): Diametric Capital, LP$1,754,6792026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:00 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.